iTrack™ Canaloplasty to be Featured at the 2025 DOG Annual Congress

California, USA, September 25, 2025 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary canaloplasty technology platform, *iTrack*™ and *iTrack*™ *Advance*, will be featured in the official scientific program of the German Society of Ophthalmology (DOG) Congress, September 25-28, 2025 in Berlin, Germany.

The iTrack results will be highlighted in a podium presentation by Dr. Karsten Klabe, and co-authored by Drs Keith Barton, David Lubeck, Nathan Kerr, and Karl Mercieca:

"Results of the iTrack Global Data Registry to Support the Role of Canaloplasty for the Treatment of Glaucoma"

(Saturday, 27 September, 14:20–14:25, Session: Glaucoma – Modern Diagnostics).

Full session details can be accessed via the DOG program.

All educational content of the DOG Annual Meeting is planned by its Program Committee. The DOG does not endorse, promote, approve, or recommend the use of any products, devices, or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

Indications for Use, US: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.*

The ab interno surgical technique is not a cleared indication for the iTrack™Advance in the USA.

** The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.*

Indications for Use, International: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

For additional information about the *iTrack™ Advance*, including safety information, please visit: https://itrack-advance.com

For media enquiries, please contact:
Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com
Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu